Stifel downgraded Orchard Therapeutics to Hold from Buy with a $16 price target after Kyowa Kirin announced a deal to acquire Orchard for $16 per American Depositary Share, or ADS, in cash, along with an additional contingent value right, or CVR, of $1.00 per ADS.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on ORTX:
- Orchard Therapeutics to be acquired by Kyowa Kirin for $16.00 per share
- Kyowa Kirin to Acquire Orchard Therapeutics
- Biotech Alert: Searches spiking for these stocks today
- Orchard Therapeutics Announces Acceptance of Biologics License Application for OTL-200 in MLD and Receives Priority Review
- Orchard Therapeutics announces FDA accepted BLA for OTL-200 in MLD